DocCode – SEQ.TXT

SCORE Placeholder Sheet for IFW Content

Application Number: 16159282 Document Date: 10/12/2018

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

- Sequence Listing

At the time of document entry (noted above):

- USPTO employees may access SCORE content via eDAN using the Supplemental Content tab, or via the SCORE web page.
- External customers may access SCORE content via PAIR using the Supplemental Content tab.

Form Revision Date: August 26, 2013

Electronically Filed

PRELIMINARY AMENDMENT Under CFR 1.115 Address to: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	REGN-008CIPCON4
	Confirmation No.	To Be Assigned
	First Named Inventor	YANCOPOULOS, GEORGE D.
	Application Number	To Be Assigned
	Filing Date	October 12, 2018
	Group Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
	Title: *"Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders"*	

Sir:

Prior to the examination of the above-referenced application on the merits, please enter the amendments below.

AMENDMENTS TO THE SPECIFICATION

Please amend paragraph [0001] on page1 of the specification to read as follows:

[0001] This application **is a continuation of U.S. Patent Application Serial No. 15/471,506, filed March 28, 2017 (now allowed) which is a continuation of U.S. Patent Application Serial No. 14/972,560, filed December 17, 2015, now U.S. Patent No. 9,669,069 issued June 6, 2017 which is a continuation of U.S. Patent Application Serial No. 13/940,370 filed July 12, 2013, now U.S. Patent No. 9,254,338 issued February 9, 2016 which** is a continuation-in-part of International Patent Application No. PCT/US2012/020855, filed on January 11, 2012, which claims the benefit of US Provisional Application Nos. 61/432,245, filed on January 13, 2011, 61/434,836, filed on January 21, 2011, and 61/561,957, filed on November 21, 2011, the contents of which are hereby incorporated by reference in their entireties.

AMENDMENTS TO THE CLAIMS

1. - 20. (**Canceled**)

21. (**New**) A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient

a single initial dose of a VEGF antagonist, followed by

one or more secondary doses of the VEGF antagonist, followed by

one or more tertiary doses of the VEGF antagonist;

wherein each secondary dose is administered 4 weeks after the immediately preceding dose; and

wherein each tertiary dose is administered on an as-needed/*pro re nata* (PRN) basis, based on visual and/or anatomical outcomes as assessed by a physician or other qualified medical professional;

wherein the VEGF antagonist is a receptor-based chimeric molecule comprising an immunoglobin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

22. (**New**) The method of claim 21, wherein the VEGF antagonist is aflibercept.

23. (**New**) The method of claim 22, wherein all doses of the VEGF antagonist are administered to the patient by intraocular administration.

24. (**New**) The method of claim 23, wherein the intraocular administration is intravitreal administration.

25. (**New**) The method of claim 24, wherein all doses of the VEGF antagonist comprise from about 0.5 mg to about 2 mg of the VEGF antagonist.

26. (**New**) The method of claim 25, wherein all doses of the VEGF antagonist comprise 0.5 mg of the VEGF antagonist.

27. (**New**) The method of claim 25, wherein all doses of the VEGF antagonist comprise 2 mg of the VEGF antagonist.

28. (**New**) The method of claim 27, wherein the angiogenic eye disorder is selected from the group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

29. (**New**) The method of claim 28 wherein the angiogenic eye disorder is age related macular degeneration.

30. (**New**) The method of claim 28 wherein the angiogenic eye disorder is diabetic retinopathy.

31. (**New**) The method of claim 28, wherein the angiogenic eye disorder is diabetic macular edema.

32. (**New**) A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient

a single initial dose of a VEGF antagonist, followed by

one or more secondary doses of the VEGF antagonist, followed by

one or more tertiary doses of the VEGF antagonist;

wherein each secondary dose is administered 4 weeks after the immediately preceding dose; and

wherein each tertiary dose is administered 12 weeks after the immediately preceding dose;

wherein the VEGF antagonist is a receptor-based chimeric molecule comprising

an immunoglobin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

33. (**New**) The method of claim 22, wherein the VEGF antagonist is aflibercept.

34. (**New**) The method of claim 23, wherein all doses of the VEGF antagonist are administered to the patient by intraocular administration.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.